Antimicrobial use and resistance among gram-negative bacilli in an Italian Intensive Care Unit (ICU)

Journal of Chemotherapy

Volumn 18, Issue 3, 2006, Pages 261-267

  Bassetti, Matteo ^a,b   Cruciani, M ^a   Righi, E ^a   Rebesco, B ^b   Fasce, R ^b   Costa, A ^a   Molinari, M P ^b   Mengoli, C ^c   Pallavicini, F Bobbio ^b   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antimicrobial use; ESBL; Gram negative bacteria; ICU; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA;

EID: 33746185704     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.3.261     Document Type: Article

References (36)

1. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274: 639-44.
2. Vaque J, Rossello J, Trilla A et al. Nosocomial infections in Spain: results of five nationwide serial prevalence surveys (EPINE project. 1990 to 1994). Infect Control Hosp Epidemiol 1996; 17: 293-7.
3. Gould I. M. Risk factors for acquisition of multiply drug-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13: Suppl. 1, 30-8.
4. Paramythiotou E, Lucet JC, Timsit JF et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38(5): 670-7.
5. D'Agata EM, Venkataraman L, DeGirolami P et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a non-outbreak period: prevalence, risk factors, and rate of infection. Crit Care Med. 1999; 27(6): 1090-5.
6. Flaherty JP, Weinstein R. A. Nosocomial infection caused by antibiotic-resistant organisms in the intensive care unit. Infect Control Hosp Epidemiol 1996; 17: 236-4.
7. Burwen DR, Banerjee SN. Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1994; 170(6): 1622-5.
8. Liu PY, Lau YJ, Hu BS et al. Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Diagn Microbiol Infect Dis. 1995; 22(3): 285-91.
9. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996; 23(4): 779-84.
10. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289(7): 885-8.
11. Barsic B, Beus I, Marton E et al. Antibiotic resistance among Gram-negative nosocomial pathogens in the intensive care unit: results of 6-year body-site monitoring. Clin Ther. 1997; 19(4): 691-700.
12. Archibald L, Phillips L, Monnet D, McGowan JE Jr. Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24(2): 211-5.
13. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004; 48(7): 2431-6.
14. Pieboji JG, Koulla-Shiro S, Ngassam P, Adiogo D, Njine T, Ndumbe P. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon. Int J Infect Dis 2004; 8(3): 147-54.
15. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18(4): 657-86.
16. Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol 1998; 36: 1446-1449.
17. Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 (Suppl S1): 59-64.
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16(3): 128-40.
19. th ed. American Society for Microbiology, Washington, D.C. 1999: 1526-1543.
20. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7, 7th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2000.
21. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard. NCCLS document M100-S13. National Committee for Clinical Laboratory Standards. Wayne, Pa. 2003.
22. Steward CD, Rasheed JK, Hubert SK et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods. J Clin Microbiol 2001; 39: 2864-2872.
23. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway, 2003.
24. Fleiss JL. Statistical methods for rates and proportions, 2nd edition. J Wiley & Sons, Inc. 1981: 143-6.
25. Agrestt A. An introduction to categorical data analysis. J Wiley & Sons, Inc. 1996.
26. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348(16): 1546-54.
27. Gaynes R, Jonathan RE. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41: 848-854
28. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumonias isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23(1): 118-24.
29. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of the antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
30. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-7.
31. DuBois SK, Marriott MS, Amyes SGB. TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7-22.
32. Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993; 17: 369-379.
33. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-8.
34. Bradford PA. Extended-Spectrum-beta-Lactamases in the 21st Century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
35. Carretto E, Emmi V, Barbarini D et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in an Italian intensive care unit: clinical and therapeutical remarks. J Chemother 2004; 16(2): 145-50.
36. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC. Spread of integron-associated VIM-type metallo-β-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 2003; 41: 822-825.